Skoner David P, Meltzer Eli O, Milgrom Henry, Stryszak Paul, Teper Ariel, Staudinger Heribert
Allegheny General Hospital, Pittsburgh, PA 15212, USA.
J Asthma. 2011 Oct;48(8):848-59. doi: 10.3109/02770903.2011.604883. Epub 2011 Aug 22.
To assess the effects of long-term mometasone furoate delivered via a dry powder inhaler (MF-DPI) on growth velocity and hypothalamic-pituitary-adrenal axis function in children with asthma.
Children aged 4-9 years with asthma (n = 187) were randomized to MF-DPI 100 μg (delivered dose; actuated dose is 110 μg) once daily in the morning (QD AM), 100 μg twice daily (BID), 200 μg QD AM, or placebo for 52 weeks followed by a 3-month follow-up period. The primary outcome was growth velocity calculated from stadiometric heights recorded at each visit. Secondary outcomes included serum and 12-h urinary cortisol, serum osteocalcin, and urinary N-telopeptide.
MF-DPI 100 μg QD AM treatment did not significantly affect growth velocity compared with placebo (-0.10 ± 0.31 cm/y, p = 0.76). When the effect of a total daily dose of 200 μg MF-DPI on growth velocity was examined, no significant effect was demonstrated for MF-DPI 100 μg BID compared with placebo (-0.64 ± 0.39 cm/y, p = 0.10), although the change in mean growth velocity with MF-DPI 200 μg QD AM reached statistical significance (-0.70 ± 0.29 cm/y, p = 0.02). The effects of all examined doses of MF-DPI on mean plasma cortisol levels were similar to cortisol changes seen in the placebo group, suggesting an absence of drug-related effects. No differences in 12-h urinary cortisol or other outcomes were observed between groups.
One year of treatment with a total daily dose of 100 μg of MF-DPI in the morning resulted in no significant difference, whereas a total daily dose of 200 μg of MF-DPI was associated with some changes in growth velocity when compared with placebo. The differences in growth velocity, and the absence of drug-related cortisol effects, support the use of a total daily dose of 100 μg of MF-DPI in children aged 4-9 years with mild persistent asthma.
评估通过干粉吸入器(MF-DPI)长期使用糠酸莫米松对哮喘儿童生长速度和下丘脑-垂体-肾上腺轴功能的影响。
187名4至9岁的哮喘儿童被随机分为四组,分别接受以下治疗,为期52周,随后有3个月的随访期:每日上午一次使用100μg MF-DPI(递送剂量;启动剂量为110μg)(QD AM),每日两次使用100μg(BID),每日上午一次使用200μg QD AM,或使用安慰剂。主要结局是根据每次就诊时测量的身高计算生长速度。次要结局包括血清和12小时尿皮质醇、血清骨钙素和尿N-端肽。
与安慰剂相比,每日上午一次使用100μg MF-DPI治疗对生长速度无显著影响(-0.10±0.31厘米/年,p = 0.76)。当检查每日总剂量200μg MF-DPI对生长速度的影响时,与安慰剂相比,每日两次使用100μg MF-DPI未显示出显著影响(-0.64±0.39厘米/年,p = 0.10),尽管每日上午一次使用200μg MF-DPI时平均生长速度的变化达到统计学显著性(-0.70±0.29厘米/年,p = 0.02)。所有检查剂量的MF-DPI对平均血浆皮质醇水平的影响与安慰剂组中观察到的皮质醇变化相似,表明不存在药物相关影响。各组之间在12小时尿皮质醇或其他结局方面未观察到差异。
与安慰剂相比,每日上午一次使用总剂量100μg的MF-DPI治疗一年无显著差异,而每日总剂量200μg的MF-DPI与生长速度的一些变化有关。生长速度的差异以及不存在药物相关的皮质醇影响,支持在4至9岁轻度持续性哮喘儿童中使用每日总剂量100μg的MF-DPI。